Steffen Mueller

Steffen Mueller is a virologist and was Assistant Professor at Stony Brook University in New York.

Mueller received his Ph.D. in molecular microbiology from Stony Brook University in 2002 in the laboratory of Eckard Wimmer.

Mueller is a co-developer of the platform technology dubbed SAVE (Synthetic Attenuated Virus Engineering),[1] a method to produce weakened synthetic viruses that are permanently prevented from regaining virulence.[2]

The method may hold the key to a new class of antiviral, so-called live, or attenuated vaccines.[3][4][5][6][7]

Mueller is co-founder and Chief Scientific Officer of Codagenix Inc., a New York-based biotechnology company engaged in the development of vaccines.

References

  1. ↑ Coleman JR, Papamichail D, Skiena S, Futcher B, Wimmer E, Mueller S (2008). "Virus attenuation by genome-scale changes in codon pair bias". Science. 320 (5884): 1784–7. doi:10.1126/science.1155761. PMC 2754401Freely accessible. PMID 18583614.
  2. ↑ Coffin JM (2008). "Attenuation by a thousand cuts". N Engl J Med. 359 (21): 2283–5. doi:10.1056/NEJMcibr0805820. PMID 19020330.
  3. ↑ Enserink M (2008). "'Biased' viruses suggest new vaccine strategy for polio and other diseases". Science. 320 (5884): 1709. doi:10.1126/science.320.5884.1709a. PMID 18583587.
  4. ↑ Robinson HL (2008). "Viral attenuation by design". Nat Biotechnol. 26 (9): 1000–1. doi:10.1038/nbt0908-1000. PMID 18779812.
  5. ↑ "Biased viruses make for good vaccines."
  6. ↑ "'Alien code' leads to faster vaccines"
  7. ↑ "In the News: Silent mutations cause a stir"
This article is issued from Wikipedia - version of the 10/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.